Organisation paid for research Program year 2025 Source: CMS Open Payments

Oregon Medical Research Center

Neither a doctor nor a teaching hospital

Research payments

$11,808,146

2,446 payments

Through program year 2025, Oregon Medical Research Center is reported as receiving $11,808,146 in research payments, across 2,446 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$812,525	130
2024	Research	$1,853,275	890
2023	Research	$1,299,936	450
2022	Research	$1,270,886	169
2021	Research	$2,762,494	385
2020	Research	$2,283,762	246
2019	Research	$1,525,267	176

Breakdown

Who paid Research payments · program years 2019–2025

Incyte Corporation $2,327,848 1,143 payments
AbbVie, Inc. $2,288,217 498 payments
Ucb SA $1,818,091 95 payments
Amgen Inc. $1,316,789 22 payments
E.R. Squibb & Sons, L.L.C. $1,075,670 31 payments
Sanofi US Services Inc. $771,867 153 payments
Novartis Pharmaceuticals Corporation $505,240 7 payments
Takeda Pharmaceuticals U.S.A., Inc. $500,151 152 payments
LEO Pharma AS $480,331 61 payments
Pfizer Inc. $440,619 145 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $1,106,225 56 payments
M15-997 $617,249 107 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo $565,647 33 payments
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) $480,160 7 payments
Interchangeability Study - ABP 654 $464,040 3 payments
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema $460,582 294 payments
A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 MG Over 32 Weeks in Adult Patients With Biopsy-Proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - Prelude $455,946 3 payments
ABP 654 P3 PsO Study $414,908 4 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $394,581 505 payments
M16-045 $334,224 45 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.